Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'

Executive Summary

Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.

You may also be interested in...



Medicare Part D Rule Offers Modest Drug Price Savings, No Point-of-Sale Rebates

CMS Administrator Verma declined to suggest a timeframe for when such a policy redirecting negotiated drug rebates to offset cost sharing in Medicare Part D might be implemented.

Part D Plan To Adjust Cost Sharing For Biosimilars Questioned By PhRMA

PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.

Part D Plan To Adjust Cost Sharing For Biosimilars Questioned By PhRMA

PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel